---
document_datetime: 2025-12-02 05:03:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sunosi.html
document_name: sunosi.html
version: success
processing_time: 0.106902
conversion_datetime: 2025-12-27 09:57:46.60587
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sunosi

[RSS](/en/individual-human-medicine.xml/67275)

##### Authorised

This medicine is authorised for use in the European Union

solriamfetol Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sunosi](#news-on)
- [More information on Sunosi](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sunosi is a medicine used to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnoea.

Narcolepsy is a long-term sleep disorder which affects the brain's ability to regulate the normal sleep-wake cycle. This leads to symptoms such as an irresistible urge to sleep, even at inappropriate times and places, and disturbed night-time sleep. Sunosi is used in patients with or without cataplexy (episodes of severe muscle weakness that can cause collapse).

Obstructive sleep apnoea is repeated interruption of breathing during sleep due to airways becoming blocked. Sunosi is used when other treatments, such as continuous positive airway pressure (CPAP, use of a ventilator to keep the airways open), have not satisfactorily improved the excessive daytime sleepiness.

Sunosi contains the active substance solriamfetol.

Expand section

Collapse section

## How is Sunosi used?

Sunosi can only be obtained with a prescription and treatment should be started by a healthcare professional experienced in treatment of narcolepsy or obstructive sleep apnoea.

Sunosi is available as tablets. The medicine should be taken once a day on waking up and the usual starting dose is 75 mg for narcolepsy or 37.5 mg for obstructive sleep apnoea. Depending on how well the medicine works, the dose may be increased up to a maximum of 150 mg once a day.

For more information about using Sunosi, see the package leaflet or contact your doctor or pharmacist.

## How does Sunosi work?

Although the way in which the active substance in Sunosi, solriamfetol, works is not fully understood, it is thought to act by increasing the levels of dopamine and noradrenaline in the brain. Dopamine and noradrenaline are neurotransmitters (chemical messengers) that carry signals between brain cells, including those that promote wakefulness.

## What benefits of Sunosi have been shown in studies?

Sunosi has been investigated in 2 main studies where it was compared with placebo (a dummy treatment). The main measures of effectiveness were the score on the Epworth sleepiness scale (a standard scale measuring daytime sleepiness ranging from 0 to 24) and the length of time the patient could stay awake in a test called the maintenance of wakefulness test.

In the first study involving 239 adults with narcolepsy, after 12 weeks of treatment, patients taking 75 mg Sunosi had an improvement of around 2.2 points on the Epworth sleepiness scale compared with placebo and patients taking 150 mg had an improvement of 3.8 points. In the maintenance of wakefulness test, patients taking 75 mg Sunosi did not have a significant improvement, while patients taking 150 mg could stay awake for 9.8 minutes longer than they could before treatment started, compared with 2.1 minutes longer for patients on placebo.

In the second study involving 476 adults with obstructive sleep apnoea, after 12 weeks of treatment, patients taking 37.5 mg, 75 mg or 150 mg Sunosi had an improvement of 1.9, 1.7 or 4.5 points, respectively, on the Epworth sleepiness scale compared with placebo. In the maintenance of wakefulness test, patients taking 37.5 mg, 75 mg or 150 mg Sunosi could stay awake for 4.7, 9.1, and 11 minutes longer, respectively, than they could before treatment started, compared with 0.2 minutes longer for patients on placebo.

## What are the risks associated with Sunosi?

The most common side effect with Sunosi, which may affect more than 1 in 10 people, is headache. Common side effects, which may affect up to 1 in 10 people, are decreased appetite, anxiety, insomnia (difficulty sleeping), irritability, bruxism (teeth grinding), dizziness, palpitations (a forceful heartbeat that may be rapid or irregular), cough, nausea (feeling sick), diarrhoea, dry mouth, abdominal pain (belly ache), constipation, vomiting, hyperhidrosis (excessive sweating), feeling jittery, chest discomfort and increased blood pressure.

Sunosi must not be used in patients who have uncontrolled hypertension (high blood pressure) or serious heart problems including heart attack in the past year, unstable angina pectoris (chest pain caused by interruptions in blood supply to the heart, that may occur at rest or without an obvious trigger) and serious cardiac arrhythmias (abnormal or irregular heartbeat). It must not be taken at the same time as certain medicines called monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping these medicines.

For the full list of side effects and restrictions with Sunosi, see the package leaflet.

## Why is Sunosi authorised in the EU?

Sunosi was shown to reduce excessive daytime sleepiness in patients with narcolepsy and obstructive sleep apnoea. The safety profile was as expected for this type of medicine. Because the medicine could cause a harmful rise in blood pressure, patients should be monitored before and during treatment. The European Medicines Agency decided that Sunosi's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sunosi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sunosi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sunosi are continuously monitored. Side effects reported with Sunosi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sunosi

Sunosi received a marketing authorisation valid throughout the EU on 16 January 2020.

Sunosi : EPAR - Medicine overview

Reference Number: EMA/40540/2020

English (EN) (125.34 KB - PDF)

**First published:** 12/02/2020

[View](/en/documents/overview/sunosi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-930)

български (BG) (146.64 KB - PDF)

**First published:**

12/02/2020

[View](/bg/documents/overview/sunosi-epar-medicine-overview_bg.pdf)

español (ES) (120.38 KB - PDF)

**First published:**

12/02/2020

[View](/es/documents/overview/sunosi-epar-medicine-overview_es.pdf)

čeština (CS) (144.35 KB - PDF)

**First published:**

12/02/2020

[View](/cs/documents/overview/sunosi-epar-medicine-overview_cs.pdf)

dansk (DA) (120.45 KB - PDF)

**First published:**

12/02/2020

[View](/da/documents/overview/sunosi-epar-medicine-overview_da.pdf)

Deutsch (DE) (123.24 KB - PDF)

**First published:**

12/02/2020

[View](/de/documents/overview/sunosi-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.23 KB - PDF)

**First published:**

12/02/2020

[View](/et/documents/overview/sunosi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (144.69 KB - PDF)

**First published:**

12/02/2020

[View](/el/documents/overview/sunosi-epar-medicine-overview_el.pdf)

français (FR) (122.27 KB - PDF)

**First published:**

12/02/2020

[View](/fr/documents/overview/sunosi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (143.67 KB - PDF)

**First published:**

12/02/2020

[View](/hr/documents/overview/sunosi-epar-medicine-overview_hr.pdf)

italiano (IT) (119.15 KB - PDF)

**First published:**

12/02/2020

[View](/it/documents/overview/sunosi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (151.29 KB - PDF)

**First published:**

12/02/2020

[View](/lv/documents/overview/sunosi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.72 KB - PDF)

**First published:**

12/02/2020

[View](/lt/documents/overview/sunosi-epar-medicine-overview_lt.pdf)

magyar (HU) (143.2 KB - PDF)

**First published:**

12/02/2020

[View](/hu/documents/overview/sunosi-epar-medicine-overview_hu.pdf)

Malti (MT) (145.57 KB - PDF)

**First published:**

12/02/2020

[View](/mt/documents/overview/sunosi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (119.96 KB - PDF)

**First published:**

12/02/2020

[View](/nl/documents/overview/sunosi-epar-medicine-overview_nl.pdf)

polski (PL) (144.21 KB - PDF)

**First published:**

12/02/2020

[View](/pl/documents/overview/sunosi-epar-medicine-overview_pl.pdf)

português (PT) (120.79 KB - PDF)

**First published:**

12/02/2020

[View](/pt/documents/overview/sunosi-epar-medicine-overview_pt.pdf)

română (RO) (141.31 KB - PDF)

**First published:**

12/02/2020

[View](/ro/documents/overview/sunosi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (143.39 KB - PDF)

**First published:**

12/02/2020

[View](/sk/documents/overview/sunosi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (141.81 KB - PDF)

**First published:**

12/02/2020

[View](/sl/documents/overview/sunosi-epar-medicine-overview_sl.pdf)

Suomi (FI) (118.41 KB - PDF)

**First published:**

12/02/2020

[View](/fi/documents/overview/sunosi-epar-medicine-overview_fi.pdf)

svenska (SV) (118.82 KB - PDF)

**First published:**

12/02/2020

[View](/sv/documents/overview/sunosi-epar-medicine-overview_sv.pdf)

Sunosi : EPAR - Risk management plan

English (EN) (783.42 KB - PDF)

**First published:** 12/02/2020

**Last updated:** 05/09/2025

[View](/en/documents/rmp/sunosi-epar-risk-management-plan_en.pdf)

## Product information

Sunosi : EPAR - Product information

English (EN) (541.58 KB - PDF)

**First published:** 12/02/2020

**Last updated:** 25/08/2025

[View](/en/documents/product-information/sunosi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-819)

български (BG) (617.22 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/bg/documents/product-information/sunosi-epar-product-information_bg.pdf)

español (ES) (518.47 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/es/documents/product-information/sunosi-epar-product-information_es.pdf)

čeština (CS) (617.16 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/cs/documents/product-information/sunosi-epar-product-information_cs.pdf)

dansk (DA) (502.22 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/da/documents/product-information/sunosi-epar-product-information_da.pdf)

Deutsch (DE) (593.87 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/de/documents/product-information/sunosi-epar-product-information_de.pdf)

eesti keel (ET) (518.63 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/et/documents/product-information/sunosi-epar-product-information_et.pdf)

ελληνικά (EL) (603.06 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/el/documents/product-information/sunosi-epar-product-information_el.pdf)

français (FR) (536.68 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/fr/documents/product-information/sunosi-epar-product-information_fr.pdf)

hrvatski (HR) (595.37 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/hr/documents/product-information/sunosi-epar-product-information_hr.pdf)

íslenska (IS) (486.02 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/is/documents/product-information/sunosi-epar-product-information_is.pdf)

italiano (IT) (496.12 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/it/documents/product-information/sunosi-epar-product-information_it.pdf)

latviešu valoda (LV) (567.65 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/lv/documents/product-information/sunosi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (584.07 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/lt/documents/product-information/sunosi-epar-product-information_lt.pdf)

magyar (HU) (632.59 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/hu/documents/product-information/sunosi-epar-product-information_hu.pdf)

Malti (MT) (638.18 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/mt/documents/product-information/sunosi-epar-product-information_mt.pdf)

Nederlands (NL) (525.08 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/nl/documents/product-information/sunosi-epar-product-information_nl.pdf)

norsk (NO) (476.25 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/no/documents/product-information/sunosi-epar-product-information_no.pdf)

polski (PL) (623.22 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/pl/documents/product-information/sunosi-epar-product-information_pl.pdf)

português (PT) (508.23 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/pt/documents/product-information/sunosi-epar-product-information_pt.pdf)

română (RO) (582.09 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/ro/documents/product-information/sunosi-epar-product-information_ro.pdf)

slovenčina (SK) (629.23 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/sk/documents/product-information/sunosi-epar-product-information_sk.pdf)

slovenščina (SL) (625 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/sl/documents/product-information/sunosi-epar-product-information_sl.pdf)

Suomi (FI) (502.25 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/fi/documents/product-information/sunosi-epar-product-information_fi.pdf)

svenska (SV) (493.75 KB - PDF)

**First published:**

12/02/2020

**Last updated:**

25/08/2025

[View](/sv/documents/product-information/sunosi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0026 10/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sunosi : EPAR - All authorised presentations

English (EN) (17.08 KB - PDF)

**First published:** 12/02/2020

[View](/en/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-144)

български (BG) (59.28 KB - PDF)

**First published:**

12/02/2020

[View](/bg/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_bg.pdf)

español (ES) (18.17 KB - PDF)

**First published:**

12/02/2020

[View](/es/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (55.02 KB - PDF)

**First published:**

12/02/2020

[View](/cs/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.61 KB - PDF)

**First published:**

12/02/2020

[View](/da/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.16 KB - PDF)

**First published:**

12/02/2020

[View](/de/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.18 KB - PDF)

**First published:**

12/02/2020

[View](/et/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.17 KB - PDF)

**First published:**

12/02/2020

[View](/el/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_el.pdf)

français (FR) (17.36 KB - PDF)

**First published:**

12/02/2020

[View](/fr/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (31.86 KB - PDF)

**First published:**

12/02/2020

[View](/hr/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (17.3 KB - PDF)

**First published:**

12/02/2020

[View](/is/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.02 KB - PDF)

**First published:**

12/02/2020

[View](/it/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (39.82 KB - PDF)

**First published:**

12/02/2020

[View](/lv/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (35.73 KB - PDF)

**First published:**

12/02/2020

[View](/lt/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (31.28 KB - PDF)

**First published:**

12/02/2020

[View](/hu/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (31.26 KB - PDF)

**First published:**

12/02/2020

[View](/mt/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.7 KB - PDF)

**First published:**

12/02/2020

[View](/nl/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.43 KB - PDF)

**First published:**

12/02/2020

[View](/no/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_no.pdf)

polski (PL) (25.52 KB - PDF)

**First published:**

12/02/2020

[View](/pl/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.67 KB - PDF)

**First published:**

12/02/2020

[View](/pt/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.79 KB - PDF)

**First published:**

12/02/2020

[View](/ro/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (31.15 KB - PDF)

**First published:**

12/02/2020

[View](/sk/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.17 KB - PDF)

**First published:**

12/02/2020

[View](/sl/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.62 KB - PDF)

**First published:**

12/02/2020

[View](/fi/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.17 KB - PDF)

**First published:**

12/02/2020

[View](/sv/documents/all-authorised-presentations/sunosi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sunosi Active substance solriamfetol hydrochloride International non-proprietary name (INN) or common name solriamfetol Therapeutic area (MeSH)

- Narcolepsy
- Sleep Apnea, Obstructive

Anatomical therapeutic chemical (ATC) code N06BA14

### Pharmacotherapeutic group

Psychoanaleptics

### Therapeutic indication

Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).

Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).

## Authorisation details

EMA product number EMEA/H/C/004893

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Atnahs Pharma Netherlands B.V.

Copenhagen Towers,

Opinion adopted 14/11/2019 Marketing authorisation issued 16/01/2020 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sunosi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (176.86 KB - PDF)

**First published:** 27/09/2021

**Last updated:** 25/08/2025

[View](/en/documents/procedural-steps-after/sunosi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sunosi-H-C-4893-P46-005 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/894270/2022

English (EN) (1.2 MB - PDF)

**First published:** 18/11/2022

[View](/en/documents/variation-report/sunosi-h-c-4893-p46-005-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Sunosi : EPAR - Public assessment report

Adopted

Reference Number: EMA/686622/20

English (EN) (2.54 MB - PDF)

**First published:** 12/02/2020

[View](/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sunosi

Adopted

Reference Number: EMA/CHMP/569229/2019

English (EN) (76.47 KB - PDF)

**First published:** 15/11/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sunosi_en.pdf)

#### News on Sunosi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 (updated)](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019-updated) 15/11/2019

#### More information on Sunosi

- [A post-authorisation safety study (PASS) to evaluate cardiovascular events in adult patients with obstructive sleep apnoea (OSA) treated with solriamfetol (JZP865-401) - post-authorisation study](https://catalogues.ema.europa.eu/study/50596)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 05/09/2025

## Share this page

[Back to top](#main-content)